AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$KYMR

Mainolfi Nello sold $3.4M of KYMR

Mainolfi Nello (Chief Executive Officer) sold 30,000 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $113.80 ($111.44–$116.12, $3.41M total) across 6 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mainolfi Nello
Published Oct 1, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KYMR
Bearish
medium confidence
Mentioned
$KYMR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRBearishLow
01

Why it matters

The disclosure provides fresh, material information that could affect short‑term price dynamics.

02

Market read

Insider sell adds new data for KYMR investors; may prompt short positions or caution.

03

What to watch

Potential upcoming clinical data or financing needs that prompted the 10b5‑1 plan.

Relevance 5/10Novelty 6/10Timing: same‑day filing

Background

Form 4 filings disclose insider transactions; a CEO sale of over $3M is noteworthy for traders.

Company-level read

Ticker impact

$KYMRBearishMedium confidence
Context

CEO Mainolfi Nello sold $3.4M of KYMR shares via a 10b5‑1 plan, reducing his stake to 666,568 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $3.4M sale by the CEO is a material insider transaction; such sales often lead to short‑term price weakness.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company‑specific.

Regional

No regional effect beyond KYMR shareholders.

Global

Limited to investors tracking insider activity in biotech.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals; the stock may hold steady.

Key entities

  • company
    Kymera Therapeutics, Inc.

    Biotech firm developing targeted protein degraders.

  • person
    Mainolfi Nello

    Chief Executive Officer of Kymera Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KYMR insider trading history →

Related articles

OCT 8
$KYMRMed

Raymond James initiates Kymera Therapeutics stock coverage with outperform rating

Raymond James initiated coverage on Kymera Therapeutics (KYMR) with an Outperform rating and $140 price target, citing its drug pipeline and upcoming trial results. The stock has gained 94% over the past year but may be overvalued. Analysts maintain a bullish stance with targets ranging from $111 to $180. Recent updates from Citi, B.Riley, and Piper Sandler also highlight the company's potential.

investing.com2 min
SEP 10
$KYMRMedAI 8/10

Kymera Therapeutics at citigroup summit: oral immunology push gains pace

Kymera Therapeutics (KYMR) presented its focus on oral immunology at Citigroup's Biopharma Summit, highlighting STAT6 and IRF5 programs. STAT6 aims to treat type 2 inflammation, with Phase III readout expected by year-end 2024. IRF5 targets autoimmune diseases, with human genetics and biological validation. The company seeks to become an independent commercial entity, focusing on immunology. Kymera's stock is up 2.54% to $118.36.

investing.com2 min
SEP 1
$KYMRMedAI 8/10

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics (KYMR) announced presentations on KT-621, its oral STAT6 degrader, at ERS and EADV congresses. The company completed enrollment in the BROADEN2 Phase 2b trial for atopic dermatitis, with topline data expected by year-end 2026. Phase 3 trials are planned for mid-2027. The BREADTH Phase 2b asthma trial is ongoing, with data expected in late 2027.

investingnews.com2 min
AUG 12
$KYMRMed

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics (KYMR) reported Q2 2026 collaboration revenue of $65M, including a $45M Gilead option fee and $20M Sanofi milestone. Cash and investments were $1.5B as of June 30, 2026, runway into 2029. R&D rose to $119.5M. KT-621 AD Phase 3 initiation is mid-2027, and asthma data is late 2027.

fool.com7 min